Home > Investors
Investor Relations Home
E-mail Page Print Page RSS Feeds E-mail Alerts IR Contacts Financial Tear Sheet 
About Us
Download Documentation 2016 Guidance Worksheet
Download Documentation ALN-PCSsc Phase 1 Clinical Results Presentation
Download Documentation Update on ABP-700
Download Documentation ALN-PCSsc Phase 1 Clinical Results Presentation
Download Documentation ABP-700 & MDCO-216 Conference Call Presentation
Corporate Profile
The Medicines Company provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise medicines and knowledge that directly impact the survival and well-being of critically ill patients.
Stock Quote
MDCO (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 1.17 (3.39%)
Data as of 12/07/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
11/15/16The Medicines Company and Alnylam Pharmaceuticals Present Positive Results from ORION-1 Phase 2 Study of Inclisiran (formerly PCSK9si)
—Study meets all interim analysis goals— —A single injection of inclisiran (300 mg) lowered ‘bad cholesterol’ (LDL-C) by an average of 51%, and up to 76%— —Two injections of inclisiran (300 mg) lowered LDL-C by an average of 57% and up to 81%— —Significant LDL-C reductions were sustained out to 180 days following a single dose— —Potential for highly-differentiated, infrequent, low volume dosing regimen of 2 o... 
Printer Friendly Version
11/13/16Alnylam Pharmaceuticals and The Medicines Company Announce Publication of Phase 1 Clinical Data with Inclisiran (ALN- PCSsc) in the New England Journal of Medicine
Interim Results from ORION-1 Phase 2 Study of Inclisiran to be Presented in Late-Breaking Clinical Trial Session at the American Heart Association Scientific Sessions on November 15, 2016 CAMBRIDGE, Mass. & PARSIPANY, N.J.--(BUSINESS WIRE)--Nov. 13, 2016-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, and The Medicines Company (Nasdaq:MDCO), a leading biopharmaceutical development and cardi... 
Printer Friendly Version
11/10/16The Medicines Company to Host Conference Call and Webcast to Review Data from Ongoing ORION-1 Phase 2 Study of PCSK9si
PARSIPPANY, N.J.--(BUSINESS WIRE)--Nov. 10, 2016-- The Medicines Company (NASDAQ: MDCO) will host a conference call and webcast on Tuesday, November 15, 2016, at 3:00 p.m., Eastern Time, to review data from the ORION-1 study of the Company’s PCSK9 synthesis inhibitor (PCSK9si). During the call, the Company’s management and PCSK9si product teams, as well as distinguished outside experts, will review data from the ongoing ORION-1 Phase 2 s... 
Printer Friendly Version
11/07/16The Medicines Company Discontinues Development of MDCO-216, its Investigational Cholesterol Efflux Promoter
— Top-line efficacy data from the MILANO-PILOT trial, which enrolled 126 patients, provide insufficient basis for further investment by the Company — — Discontinuation will enable the Company to reallocate and focus substantial additional capital onto the development of its PCSK9 synthesis inhibitor — — Results from the MILANO-PILOT trial will be presented in the Late-Breaking Clinical Trial Session at American Heart Association ... 
Printer Friendly Version
Upcoming Events
There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.